Marta Cremonesi1, Laura Gilardi2, Mahila Esmeralda Ferrari3, Gaia Piperno4, Laura Lavinia Travaini2, Robert Timmerman5, Francesca Botta3, Guido Baroni6, Chiara Maria Grana2, Sara Ronchi4, Delia Ciardo4, Barbara Alicja Jereczek-Fossa4,7, Cristina Garibaldi8, Roberto Orecchia7,9. 1. Radiation Research Unit, European Institute of Oncology, Milano, Italy. marta.cremonesi@ieo.it. 2. Division of Nuclear Medicine, European Institute of Oncology, Milano, Italy. 3. Medical Physics Unit, European Institute of Oncology, Milano, Italy. 4. Division of Radiation Oncology, European Institute of Oncology, Milano, Italy. 5. Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 6. Department of Electronics, Information and Bioengineering, Politecnico di Milano University, Milano, Italy. 7. Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy. 8. Radiation Research Unit, European Institute of Oncology, Milano, Italy. 9. Department of Medical Imaging and Radiation Sciences, European Institute of Oncology, Milano, Italy.
Abstract
BACKGROUND: Non-Small Cell Lung Cancer (NSCLC) is characterized by aggressiveness and includes the majority of thorax malignancies. The possibility of early stratification of patients as responsive and non-responsive to radiotherapy with a non-invasive method is extremely appealing. The distribution of the Fluorodeoxyglucose (18F-FDG) in tumours, provided by Positron-Emission-Tomography (PET) images, has been proved to be useful to assess the initial staging of the disease, recurrence, and response to chemotherapy and chemo-radiotherapy (CRT). OBJECTIVES: In the last years, particular efforts have been focused on the possibility of using ad interim 18F-FDG PET (FDGint) to evaluate response already in the course of radiotherapy. However, controversial findings have been reported for various malignancies, although several results would support the use of FDGint for individual therapeutic decisions, at least in some pathologies. The objective of the present review is to assemble comprehensively the literature concerning NSCLC, to evaluate where and whether FDGint may offer predictive potential. METHODS: Several searches were completed on Medline and the Embase database, combining different keywords. Original papers published in the English language from 2005 to 2016 with studies involving FDGint in patients affected by NSCLC and treated with radiation therapy or chemo-radiotherapy only were chosen. RESULTS: Twenty-one studies out of 970 in Pubmed and 1256 in Embase were selected, reporting on 627 patients. CONCLUSION: Certainly, the lack of univocal PET parameters was identified as a major drawback, while standardization would be required for best practice. In any case, all these papers denoted FDGint as promising and a challenging examination for early assessment of outcomes during CRT, sustaining its predictivity in lung cancer.
BACKGROUND:Non-Small Cell Lung Cancer (NSCLC) is characterized by aggressiveness and includes the majority of thorax malignancies. The possibility of early stratification of patients as responsive and non-responsive to radiotherapy with a non-invasive method is extremely appealing. The distribution of the Fluorodeoxyglucose (18F-FDG) in tumours, provided by Positron-Emission-Tomography (PET) images, has been proved to be useful to assess the initial staging of the disease, recurrence, and response to chemotherapy and chemo-radiotherapy (CRT). OBJECTIVES: In the last years, particular efforts have been focused on the possibility of using ad interim 18F-FDG PET (FDGint) to evaluate response already in the course of radiotherapy. However, controversial findings have been reported for various malignancies, although several results would support the use of FDGint for individual therapeutic decisions, at least in some pathologies. The objective of the present review is to assemble comprehensively the literature concerning NSCLC, to evaluate where and whether FDGint may offer predictive potential. METHODS: Several searches were completed on Medline and the Embase database, combining different keywords. Original papers published in the English language from 2005 to 2016 with studies involving FDGint in patients affected by NSCLC and treated with radiation therapy or chemo-radiotherapy only were chosen. RESULTS: Twenty-one studies out of 970 in Pubmed and 1256 in Embase were selected, reporting on 627 patients. CONCLUSION: Certainly, the lack of univocal PET parameters was identified as a major drawback, while standardization would be required for best practice. In any case, all these papers denoted FDGint as promising and a challenging examination for early assessment of outcomes during CRT, sustaining its predictivity in lung cancer.
Authors: Evangelia Skoura; Ioannis E Datseris; Ioannis Platis; Georgios Oikonomopoulos; Konstantinos N Syrigos Journal: Clin Lung Cancer Date: 2011-12-01 Impact factor: 4.785
Authors: M Min; P Lin; M Lee; I Ho Shon; M Lin; D Forstner; M T Tieu; A Chicco; V Bray; A Fowler Journal: Clin Oncol (R Coll Radiol) Date: 2016-01-11 Impact factor: 4.126
Authors: Willem Grootjans; Edwin A Usmanij; Wim J G Oyen; Erik H F M van der Heijden; Eric P Visser; Dimitris Visvikis; Mathieu Hatt; Johan Bussink; Lioe-Fee de Geus-Oei Journal: Radiother Oncol Date: 2016-05-10 Impact factor: 6.280
Authors: Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau Journal: J Nucl Med Date: 2012-11-30 Impact factor: 10.057
Authors: Feng-Ming Spring Kong; Kirk A Frey; Leslie E Quint; Randall K Ten Haken; James A Hayman; Marc Kessler; Indrin J Chetty; Daniel Normolle; Avraham Eisbruch; Theodore S Lawrence Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Robert H Press; Hui-Kuo G Shu; Hyunsuk Shim; James M Mountz; Brenda F Kurland; Richard L Wahl; Ella F Jones; Nola M Hylton; Elizabeth R Gerstner; Robert J Nordstrom; Lori Henderson; Karen A Kurdziel; Bhadrasain Vikram; Michael A Jacobs; Matthias Holdhoff; Edward Taylor; David A Jaffray; Lawrence H Schwartz; David A Mankoff; Paul E Kinahan; Hannah M Linden; Philippe Lambin; Thomas J Dilling; Daniel L Rubin; Lubomir Hadjiiski; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-30 Impact factor: 7.038
Authors: Janna E van Timmeren; Sara Carvalho; Ralph T H Leijenaar; Esther G C Troost; Wouter van Elmpt; Dirk de Ruysscher; Jean-Pierre Muratet; Fabrice Denis; Tanja Schimek-Jasch; Ursula Nestle; Arthur Jochems; Henry C Woodruff; Cary Oberije; Philippe Lambin Journal: PLoS One Date: 2019-06-03 Impact factor: 3.240
Authors: M Unterrainer; C Eze; H Ilhan; S Marschner; O Roengvoraphoj; N S Schmidt-Hegemann; F Walter; W G Kunz; P Munck Af Rosenschöld; R Jeraj; N L Albert; A L Grosu; M Niyazi; P Bartenstein; C Belka Journal: Radiat Oncol Date: 2020-04-21 Impact factor: 3.481
Authors: Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei Journal: Radiother Oncol Date: 2022-01-20 Impact factor: 6.901